Patents by Inventor Bernd Eschgfaller

Bernd Eschgfaller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified L-Nucleic Acid
    Publication number: 20200010833
    Abstract: A modified L-nucleic acid, containing an L-nucleic acid part conjugated to a non-L-nucleic acid part is described. The conjugate has extended retention time in and demonstrates a delayed elimination from an organism.
    Type: Application
    Filed: September 18, 2019
    Publication date: January 9, 2020
    Applicant: NOXXON Pharma AG
    Inventors: Christian Lange, Bernd Eschgfaller, Sven Klussmann
  • Modified L-Nucleic Acid
    Publication number: 20180179541
    Abstract: A modified L-nucleic acid, containing an L-nucleic acid part conjugated to a non-L-nucleic acid part is described. The conjugate has extended retention time in and demonstrates a delayed elimination from an organism.
    Type: Application
    Filed: February 15, 2018
    Publication date: June 28, 2018
    Applicant: NOXXON Pharma AG
    Inventors: Christian Lange, Bernd Eschgfaller, Sven Klussmann
  • Modified L-Nucleic Acid
    Publication number: 20160376594
    Abstract: A modified L-nucleic acid, containing an L-nucleic acid part conjugated to a non-L-nucleic acid part is described. The conjugate has extended retention time in and demonstrates a delayed elimination from an organism.
    Type: Application
    Filed: September 1, 2016
    Publication date: December 29, 2016
    Applicant: NOXXON Pharma AG
    Inventors: Christian Lange, Bernd Eschgfaller, Sven Klussmann
  • Modified L-nucleic Acid
    Publication number: 20150038562
    Abstract: A modified L-nucleic acid, containing an L-nucleic acid part conjugated to a non-L-nucleic acid part is described. The conjugate has extended retention time in and demonstrates a delayed elimination from an organism.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Inventors: Christian Lange, Bernd Eschgfaller, Sven Klussmann
  • Modified L-Nucleic Acid
    Publication number: 20120214868
    Abstract: A modified L-nucleic acid, containing an L-nucleic acid part conjugated to a non-L-nucleic acid part is described. The conjugate has extended retention time in and demonstrates a delayed elimination from an organism.
    Type: Application
    Filed: March 26, 2012
    Publication date: August 23, 2012
    Inventors: Christian Lange, Bernd Eschgfäller, Sven Klussmann
  • CGRP binding nucleic acids
    Patent number: 7879991
    Abstract: The invention relates to an antagonist for CGRP and amylin, whereby the antagonist is a nucleic acid and said nucleic acid binds to CGRP or amylin. Said nucleic acid preferably comprises an L-nucleotide.
    Type: Grant
    Filed: May 6, 2003
    Date of Patent: February 1, 2011
    Assignee: NOXXON Pharma AG
    Inventors: Axel Vater, Christian Maasch, Florian Jarosch, Mathias Bell, Steffen Helmling, Bernd Eschgfäller, Elisabeth Moyroud, Sandra Stark, Sven Klussmann, Thorsten Ruppert, Gregor Bahrenberg, Clemens Gillen, Klaus Schiene
  • Modified L-Nucleic Acid
    Publication number: 20100081710
    Abstract: A modified L-nucleic acid, containing an L-nucleic acid part conjugated to a non-L-nucleic acid part is described. The conjugate has extended retention time in and demonstrates a delayed elimination from an organism.
    Type: Application
    Filed: August 13, 2009
    Publication date: April 1, 2010
    Applicant: NOXXON PHARMA AG
    Inventors: Christian Lange, Bernd Eschgfaller, Sven Klussmann
  • Modified L-nucleic acid
    Patent number: 7629456
    Abstract: The present invention relates to a modified L-nucleic acid, comprising a L-nucleic acid part and a non-L-nucleic acid part, whereby the L-nucleic acid part is conjugated to the non-L-nucleic acid part and the conjugation of the L-nucleic acid part with the non-L-nucleic acid past leads to a slowed elimination out of the organism, in comparison with a L-nucleic acid which only comprises the L-nucleic acid part, said L-nucleic acid part being a spiegelmer.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: December 8, 2009
    Assignee: NOXXON Pharma AG
    Inventors: Christian Lange, Bernd Eschgfäller, Sven Klussmann
  • Cgrp binding nucleic acids
    Publication number: 20060183700
    Abstract: The invention relates to an antagonist for CGRP and amylin, whereby the antagonist is a nucleic acid and said nucleic acid binds to CGRP or amylin. Said nucleic acid preferably comprises an L-nucleotide.
    Type: Application
    Filed: May 6, 2003
    Publication date: August 17, 2006
    Applicant: NOXXON Pharma AG
    Inventors: Axel Vater, Christian Maasch, Florian Jarosch, Mathias Bell, Steffen Helmling, Bernd Eschgfaller, Elisabeth Moyroud, Sandra Stark, Sven Klussmann, Thorsten Ruppert, Gregor Bahrenberg, Clemens Gillen, Klaus Schiene
  • Modified l-nucleic acid
    Publication number: 20060003326
    Abstract: The present invention relates to a modified L-nucleic acid, comprising a L-nucleic acid part and a non-L-nucleic acid part, whereby the L-nucleic acid part is conjugated to the non-L-nucleic acid part and the conjugation of the L-nucleic acid part with the non-L-nucleic acid past leads to a slowed elimination out of the organism, in comparison with a L-nucleic acid which only comprises the L-nucleic acid part, said L-nucleic acid part being a spiegelmer.
    Type: Application
    Filed: October 25, 2002
    Publication date: January 5, 2006
    Inventors: Christian Lange, Bernd Eschgfaller, Sven Klussmann